OREANDA-NEWS Johnson & Johnson is buying V-Wave Ltd., a company focused on developing innovative treatments for patients with heart failure, the J&J press service said.

The company will pay $600 million for V-Wave, as well as up to $1.1 billion after the deal passes certain regulatory and commercial stages.

After the deal closes, V-Wave will become part of J&J's medical technology division.

V-Wave, established in 2009, has offices in Israel and the USA. She is the developer of cardiovascular implant technology specifically designed for the treatment of reduced ejection fraction (HFrEF) heart failure. The V-Wave bypass implant is designed to reduce the filling pressure of the left atrium in patients with chronic heart failure.

The V-Wave device has been approved by the Food and Drug Administration (FDA) USA in 2019.

The deal is expected to close by the end of 2024.